

KURZPROTOKOLL
Checkmate CA209-817

Öffentlicher Titel	Nivolumab und Ipilimumab bei fortgeschrittenem Nicht-kleinzelligem Lungenkrebs
Wissenschaftl. Titel	A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants With Advanced Malignancies.
Kurztitel	Checkmate CA209-817
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig
Studienphase	Phase III/IV
Erkrankung	Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Zweitlinie oder höher Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Erstlinie
Einschlusskriterien	<ul style="list-style-type: none">- Histologically confirmed Stage 4 or recurrent non-small cell lung cancer- Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)- No prior systemic anticancer therapy (including EGFR and ALK inhibitors)- Tissue or Programmed death-ligand 1 (PD-L1) results available
Ausschlusskriterien	<ul style="list-style-type: none">- Untreated brain metastases- An active malignancy that requires concurrent intervention- Active, known or suspected autoimmune disease- Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer
Alter	18 Jahre und älter
Sponsor	Bristol-Myers Squibb
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02869789 EudraCT 2016-002621-10